Who are Olopatadine Nasal Spray's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluticasone/Azelastine nasal spray, Morphine-Promethazine, fexofenadine HCl, Hydroxyzine HCL, alcaftadine 0.25% ophthalmic solution, olopatadine (OLO).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olopatadine-nasal-spray.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Olopatadine Nasal Spray — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olopatadine Nasal Spray (Olopatadine Nasal Spray) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective H1-receptor antagonist / mast cell stabilizer. Area: Allergy / Immunology.

marketed Selective H1-receptor antagonist / mast cell stabilizer H1 histamine receptor Allergy / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Olopatadine Nasal Spray (Olopatadine Nasal Spray) — ORA, Inc.. Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the nasal mucosa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Olopatadine Nasal Spray TARGET	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
fexofenadine HCl	fexofenadine HCl	Sanofi	marketed	Second-generation H1-receptor antagonist (non-sedating antihistamine)	H1 histamine receptor
Hydroxyzine HCL	Hydroxyzine HCL	National Cancer Institute (NCI)	marketed	First-generation H1 antihistamine	H1 histamine receptor
alcaftadine 0.25% ophthalmic solution	alcaftadine 0.25% ophthalmic solution	Allergan	marketed	Selective H1-receptor antagonist	H1 histamine receptor
olopatadine (OLO)	olopatadine (OLO)	University of Chicago	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective H1-receptor antagonist / mast cell stabilizer class)

ORA, Inc. · 1 drug in this class
University of Chicago · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olopatadine Nasal Spray — Competitive Intelligence Brief. https://druglandscape.com/ci/olopatadine-nasal-spray. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab